We are live on ! Find out more
PCM

Pavaki Capital Management Portfolio holdings

AUM $287M
This Fund
S&P 500
This Quarter Est. Return
+0.76%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$235M
AUM Growth
-$19.8M
Cap. Flow
+$10.3M
Cap. Flow %
4.36%
Top 10 Hldgs %
50.47%
Holding
162
New
31
Increased
16
Reduced
7
Closed
6

Top Buys

Rank Stock Value
1
CVX icon
Chevron
CVX
+$13.2M
2
EWS icon
iShares MSCI Singapore ETF
EWS
+$1.69M
3
ESPR
Esperion Therapeutics
ESPR
+$1.3M
4
B
Barrick Mining
B
+$1.27M
5
NAMS icon
NewAmsterdam Pharma
NAMS
+$1.19M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$8.8M
2
SPRY icon
ARS Pharmaceuticals
SPRY
+$5.71M
3
OGN icon
Organon & Co
OGN
+$3.01M
4
ROIV icon
Roivant Sciences
ROIV
+$868K
5
ALT icon
Altimmune
ALT
+$778K

Sector Composition

Rank Sector Weight
1 Miscellaneous 41.44%
2 Healthcare 20.32%
3 Materials 13.21%
4 Energy 8.84%
5 Technology 4.85%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CVNA icon
1
CALL
Carvana
CVNA
$45.8B
$38M 16.16%
605,000
+30,000
+5% +$2.23M
TSLA icon
2
CALL
Tesla
TSLA
$1.39T
$16.2M 6.87%
43,500
+6,000
+16% +$2.47M
CVX icon
3
Chevron
CVX
$401B
$15.4M 6.55%
74,500
+72,500
+3,625% +$13.2M
MIST icon
4
Milestone Pharmaceuticals
MIST
$102M
$10.8M 4.58%
9,062,848
+563,933
+7% +$987K
B
5
Barrick Mining
B
$67.9B
$9.04M 3.84%
221,500
+27,500
+14% +$1.27M
PLTR icon
6
CALL
Palantir
PLTR
$449B
$7.39M 3.14%
50,500
+2,000
+4% +$306K
REGN icon
7
Regeneron Pharmaceuticals
REGN
$77.3B
$6.1M 2.59%
7,900
-11,500
-59% -$8.8M
DIS icon
8
Walt Disney
DIS
$182B
$5.88M 2.5%
61,000
– –
BTG icon
9
B2Gold
BTG
$7.05B
$5.35M 2.27%
1,180,000
+20,000
+2% +$100K
SPRY icon
10
ARS Pharmaceuticals
SPRY
$438M
$4.63M 1.97%
576,200
-595,800
-51% -$5.71M
QQQ icon
11
PUT
Invesco QQQ Trust
QQQ
$495B
$4.62M 1.96%
8,000
+3,000
+60% +$1.82M
INTC icon
12
Intel
INTC
$613B
$4.41M 1.87%
100,000
– –
ARQT icon
13
Arcutis Biotherapeutics
ARQT
$3.36B
$4.41M 1.87%
187,000
-15,000
-7% -$383K
TXT icon
14
Textron
TXT
$13.4B
$3.74M 1.59%
42,700
– –
NEM icon
15
Newmont
NEM
$123B
$3.52M 1.49%
32,500
– –
CGAU
16
Centerra Gold
CGAU
$4.31B
$3.5M 1.49%
197,000
– –
NVDA icon
17
NVIDIA
NVDA
$5.49T
$2.79M 1.19%
16,000
– –
QQQ icon
18
CALL
Invesco QQQ Trust
QQQ
$495B
$2.6M 1.1%
4,500
– –
APP icon
19
CALL
Applovin
APP
$102B
$2.47M 1.05%
6,200
– –
SPY icon
20
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$815B
$2.41M 1.02%
3,700
+500
+16% +$340K
LGND icon
21
Ligand Pharmaceuticals
LGND
$6.19B
$2.22M 0.94%
11,100
– –
SSRM icon
22
SSR Mining
SSRM
$6.92B
$2.2M 0.94%
75,000
– –
AVGO icon
23
CALL
Broadcom
AVGO
$1.7T
$2.17M 0.92%
7,000
– –
RPRX icon
24
Royalty Pharma
RPRX
$25.9B
$2.11M 0.9%
44,000
– –
HRMY icon
25
Harmony Biosciences
HRMY
$2.29B
$2.04M 0.87%
73,000
– –
1
2 3 4 5

Similar funds

OCM
Ogborne Capital Management San Francisco, California $287M AUM 14.05% 1-Year Est. Return
RSC
Red Spruce Capital Berwyn, Pennsylvania $287M AUM 38.81% 1-Year Est. Return
MC
Metavasi Capital Larchmont, New York $287M AUM 97.9% 1-Year Est. Return
QFW
QTR Family Wealth Lake Mary, Florida $287M AUM 40.55% 1-Year Est. Return
SRWM
Shira Ridge Wealth Management Larkspur, California $287M AUM 23.34% 1-Year Est. Return
ORC
O'Rourke & Company Boston, Massachusetts $287M AUM 23.01% 1-Year Est. Return
MPAM
Murphy Pohlad Asset Management Eden Prairie, Minnesota $287M AUM 38.81% 1-Year Est. Return
AWMT
AAFMAA Wealth Management & Trust Fayetteville, North Carolina $286M AUM 19.57% 1-Year Est. Return

Pavaki Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, Pavaki Capital Management held 162 positions worth $235M, down 7.8% from $255M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Pavaki Capital Management deployed $10.3M of net new capital in Q1 2026, opening 31 new positions and adding to 16 existing holdings. Its largest new stake was iShares MSCI Singapore ETF: 60,000 shares worth $1.69M.

By sector, the portfolio is most concentrated in Miscellaneous at 41% of assets, down from 44% a quarter earlier, followed by Healthcare and Materials.

On the sell side, the largest reduction was Regeneron Pharmaceuticals, an estimated $8.8M trimmed.

  • Pavaki Capital Management's largest Q1 2026 buy was iShares MSCI Singapore ETF: 60,000 shares worth $1.69M.
  • Pavaki Capital Management added most to Chevron in Q1 2026, an estimated $13.2M increase.
  • Pavaki Capital Management's biggest Q1 2026 reduction was Regeneron Pharmaceuticals, cutting an estimated $8.8M.
  • Pavaki Capital Management fully exited Roivant Sciences in Q1 2026, selling an estimated $868K.
  • Pavaki Capital Management's ten largest holdings make up 50% of its $235M portfolio in Q1 2026.
  • Pavaki Capital Management opened 31 new positions and closed 6 in Q1 2026.
  • Pavaki Capital Management's portfolio value fell 7.8% quarter-over-quarter to $235M.

Based on Pavaki Capital Management's 13F filing for Q1 2026, filed 7 Aug 2026.